We are a clinical stage company developing a sustained-release drug delivery platform with application across a broad range of conditions, including pain and cancer medications. We have two products in three Phase II trials and a third about to begin its Phase II trial. Our first product is a locally injected non-opioid pain medication designed to address large markets with high unmet needs. It has the potential to provide effective, long-lasting pain management over longer periods with fewer side effects than the standard of care; it offers up to four weeks of non-addictive pain relief from a single injection. A Phase I clinical trial has been followed by two Phase II studies now underway, with the recent successful completion of an interim data review. We anticipate completing enrollment in mid 2025. In addition, we have initiated a Phase II study in a second product, an oncology medication with an orphan indication, Upper Tract Urethral Carcinoma.